Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pooled Analysis of Trabectedin Efficacy in Myxoid/Round Cell Liposarcoma from Three Prospective Clinical Trials.

Cancers·2026
Same author

The WHO Classification of Genetic Tumour Syndromes: Considerations for Genetics.

Clinical genetics·2026
Same author

LPAR4 mediates resistance to interferon-induced stress in soft tissue sarcoma.

Science advances·2026
Same author

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.

Cancer research communications·2026
Same author

Turning Difficult Conversations into Opportunities.

Annals of surgery·2026
Same author

Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell States.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jun 17, 2026

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
10:49

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

20.6K

High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience.

Lewis F Nasr1, Marianne Zoghbi1, Rossana Lazcano2

  • 1Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Cancers
|May 11, 2024
PubMed
Summary

Immune checkpoint blockade (ICB) shows promise for advanced undifferentiated pleomorphic sarcomas (UPSs), with a 32% 6-month progression-free survival (PFS). Real-world data indicate manageable toxicity and improved outcomes for partial or stable responders.

Keywords:
anti-PD1clinicalimmunotherapyreal worldsarcomasurvivalundifferentiated pleomorphic sarcomas

More Related Videos

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

3.3K
Expanding the Comprehension of the Tumor Microenvironment using Mass Spectrometry Imaging of Formalin-Fixed and Paraffin-Embedded Tissue Samples
06:47

Expanding the Comprehension of the Tumor Microenvironment using Mass Spectrometry Imaging of Formalin-Fixed and Paraffin-Embedded Tissue Samples

Published on: June 29, 2022

2.2K

Related Experiment Videos

Last Updated: Jun 17, 2026

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
10:49

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

20.6K
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

3.3K
Expanding the Comprehension of the Tumor Microenvironment using Mass Spectrometry Imaging of Formalin-Fixed and Paraffin-Embedded Tissue Samples
06:47

Expanding the Comprehension of the Tumor Microenvironment using Mass Spectrometry Imaging of Formalin-Fixed and Paraffin-Embedded Tissue Samples

Published on: June 29, 2022

2.2K

Area of Science:

  • Oncology
  • Immunotherapy
  • Sarcoma Research

Background:

  • Undifferentiated pleomorphic sarcomas (UPSs) are common soft-tissue sarcomas.
  • Limited real-world data exist on immune checkpoint blockade (ICB) efficacy in UPS and other high-grade pleomorphic sarcomas.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of ICB in advanced UPS and other high-grade pleomorphic sarcomas.
  • To describe real-world outcomes at a single institution.

Main Methods:

  • Retrospective, observational study of 36 patients with metastatic pleomorphic sarcomas treated with ICB.
  • Data collected from MD Anderson Cancer Center between January 2015 and January 2023.
  • Exclusion of patients in unpublished clinical trials.

Main Results:

  • Median progression-free survival (PFS) was 2.9 months; 6-month PFS was 32%.
  • Median overall survival (OS) was 12.9 months; 24-month OS was 29%.
  • Best response, prior radiation therapy, and ICB type impacted PFS; toxicity was manageable.

Conclusions:

  • Real-world data support ICB efficacy, with a 6-month PFS of 32%.
  • Patients achieving partial or stable responses demonstrated significantly better PFS.
  • ICB is a viable treatment option with manageable toxicity for advanced pleomorphic sarcomas.